City of Hope surgical researchers are assessing whether pressurized intraperitoneal aerosolized chemotherapy can be an effective way to deliver chemotherapy to abdominal cancer patients.
Two phase I/II trials that evaluated the safety and efficacy of CD30 CAR-T cell therapy in patients with relapsed/refractory Hodgkin lymphoma showed a high rate of durable complete responses and very favorable safety profile using autologous CD30 CAR-T cell therapy.
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute conducted a retrospective study that could refine predicted survival outcomes and treatment in younger adults with acute leukemia.
Scientists have developed the most accurate computing method to date to reconstruct the patchwork of genetic faults within tumors and their history during disease development, in new research funded by Cancer Research UK and published in Nature Genetics.
Specific genomic biomarkers can be used to identify glioma patients most likely to benefit from post-radiation chemotherapy and serve as a significant predictor of overall and progression-free survival, according to data published by researchers at The Ohio State University. Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase III study.
The GioTag study demonstrated that sequential Gilotrif (afatinib) and osimertinib contributed to a median overall survival of nearly four years (47.6 months) among U.S. patients (129) with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance mutation, T790M.
Researchers at Roswell Park Comprehensive Center found that people diagnosed with breast cancers that are small but invasive could benefit from hormone treatment. The findings were published in JAMA Network Open.
Researchers at the University of Kansas Medical Center have begun a study exploring an investigational drug, ATI-450, intended to fight the cytokine storm associated with COVID-19.
The University of Minnesota has begun a clinical study to test whether a novel cell therapy currently under clinical investigation as a treatment for acute myeloid leukemia and lymphoma can be effective as a treatment for COVID-19.
